Lyron L. Bentovim - Feb 29, 2024 Form 4 Insider Report for Glimpse Group, Inc. (VRAR)

Role
President and CEO, Director
Signature
/s/ Lyron L. Bentovim
Stock symbol
VRAR
Transactions as of
Feb 29, 2024
Transactions value $
$0
Form type
4
Date filed
3/5/2024, 10:33 AM
Previous filing
Aug 26, 2024
Next filing
May 22, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRAR Stock Option (Right to Purchase) Disposed to Issuer $0 -90.2K -100% $0.00* 0 Feb 29, 2024 Common Stock 90.2K Direct F1, F2
transaction VRAR Stock Option (Right to Purchase) Award $0 +72.2K +5.96% $0.00 1.28M Mar 1, 2024 Common Stock 72.2K Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the forfeiture of fully vested options to purchase an aggregate of 90,188 shares of common stock granted under the issuer's 2016 equity incentive plan, as amended (the "2016 Plan"), consisting of options to purchase (i) 32,508 shares of common stock granted on August 1, 2018 with an exercise price of $4.00/share, (ii) 6,037 shares of common stock and 4,799 shares of common stock granted on September 1, 2019 with an exercise price of $4.00/share, (iii) 22,222 shares of common stock and 6,674 shares of common stock granted on January 1, 2020 with an exercise price of $4.50/share, (iv) 2,333 shares of common stock granted on May 1, 2020 with an exercise price of $4.50/share, (v) 1,167 shares of common stock granted on July 1, 2020 with an exercise price of $4.50/share, and (vi) 14,448 shares of common stock granted on January 1, 2021 with an exercise price of $4.50/share.
F2 The options in footnote (1) were to expire 10 years from their respective grant dates.
F3 Mr. Bentovim was granted options to purchase an aggregate of 72,153 shares of the issuer's common stock under the 2016 Plan on March 1, 2023, consisting of (i) options to purchase 24,051 shares of common stock, at an exercise price of $3.00 per share, which options vest on March 1, 2025, (ii) options to purchase 24,051 shares of common stock, at an exercise price of $2.50 per share, which options vest on March 1, 2026, and (ii) options to purchase 24,051 shares of common stock, at an exercise price of $2.00 per share, which options vest on March 1, 2027. The foregoing options are set to expire seven years from the grant date.